1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
United States
702 514 4174
https://www.pasithea.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 8
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman | 250k | N/A | 1948 |
Dr. Tiago Reis Marques M.D., Ph.D. | CEO & Director | 480k | N/A | 1977 |
Mr. Daniel H. Schneiderman | Chief Financial Officer | 345,94k | N/A | 1978 |
Dr. Graeme Currie Ph.D. | Chief Development Officer | 346,62k | N/A | 1967 |
Dr. Yassine Bendiabdallah Ph.D. | COO & Head of UK Clinics | N/A | N/A | 1984 |
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
El ISS Governance QualityScore de Pasithea Therapeutics Corp., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.